The authors reply

New England Journal of Medicine

Volumn 375, Issue 9, 2016, Pages 900-901

  Papaemmanuil, Elli ^a   Döhner, Hartmut ^b   Campbell, Peter J ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CONSOLIDATION CHEMOTHERAPY; EVENT FREE SURVIVAL; GENE MUTATION; HUMAN; IDH1 GENE; IDH2 GENE; INDUCTION CHEMOTHERAPY; LETTER; NPM1 GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ACUTE DISEASE; CHROMOSOME ABERRATION; GENETICS; GENOMICS; LEUKEMIA; MYELOID LEUKEMIA;

ACUTE DISEASE; CHROMOSOME ABERRATIONS; GENOMICS; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, ACUTE;

EID: 84985997639     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1608739     Document Type: Letter

References (0)